Skip to main content
$146.00 $1.99 (1.4%)

12:12 PM EDT on 04/20/21

Seagen Inc (NASDAQ:SGEN)

CAPS Rating: 4 out of 5

A biotechnology company, which develops monoclonal antibody-based therapies for the treatment of cancer and autoimmune diseases.

Current Price $146.00 Mkt Cap $26.1B
Open $144.89 P/E Ratio 41.03
Prev. Close $144.01 Div. (Yield) $0.00 (0.0%)
Daily Range $144.34 - $146.94 Volume 231,910
52-Wk Range $134.51 - $213.94 Avg. Daily Vol. 1,099,210

Caps

How do you think NASDAQ:SGEN will perform against the market?

Add Stock to CAPS Watchlist

All Players

487 Outperform
30 Underperform
 

All-Star Players

105 Outperform
6 Underperform
 

Wall Street

0 Outperform
0 Underperform
 

Top NASDAQ:SGEN Bull/Bear Pitches

The best Bull and Bear pitches based on recency and number of recommendations.

TMFEBCapital (97.19)
Submitted October 30, 2020

Sig revenue expansion opportunity from recent launches, plus potential blockbuster in ladiratuzumab vedotin moving through trials. Merck 'partnership' provides multiple opps for combination approaches.

PDTBiotech (68.91)
Submitted July 07, 2011

$2.34B for a drug which treats HL and ALCL seems very, very rich, even when taking SGEN's strong balance sheet into account. Very cool platform, but the target for brentuximab vedotin is expressed on a narrow enough set of tumor types to keep this… More

Recent Community Commentary

Read the most recent pitches from players about SGEN.

Recs

2
Member Avatar TMFEBCapital (97.19) Submitted: 10/30/2020 1:35:34 PM : Outperform Start Price: $173.04 NASDAQ:SGEN Score: -30.14

Sig revenue expansion opportunity from recent launches, plus potential blockbuster in ladiratuzumab vedotin moving through trials. Merck 'partnership' provides multiple opps for combination approaches.

Recs

0
Member Avatar wrciii (82.70) Submitted: 5/26/2020 12:29:06 PM : Outperform Start Price: $151.94 NASDAQ:SGEN Score: -39.31

Salveen R 246

Recs

0
Member Avatar IndyAnthony (71.74) Submitted: 4/20/2020 6:27:29 PM : Outperform Start Price: $138.94 NASDAQ:SGEN Score: -43.84

Biotech on the rise with new breast cancer drug got the nod from the FDA.

Leaderboard

Find the members with the highest scoring picks in SGEN.

Score Leader

lloydvon

lloydvon (< 20) Score: +2,917.46

The Score Leader is the player with the highest score across all their picks in SGEN.

Top
Pick
Member Name Member
Rating
Start
Date
Call Time
Frame
Start
Price
Stock
Gain
Index
Gain
Score Commentary
lloydvon < 20 8/30/2006 Outperform 1Y $4.48 +3,152.79% +235.33% +2,917.46 1 Comment
Zipsdad < 20 10/4/2006 Outperform 1Y $4.67 +3,020.45% +228.57% +2,791.88 0 Comment
twildstar 91.83 10/11/2006 7/20/2012 Outperform NS $4.93 +2,855.88% +222.15% +2,633.74 0 Comment
vkowalczuk 82.53 10/19/2006 Outperform 1Y $5.10 +2,757.35% +220.45% +2,536.90 1 Comment
RAIDERFAN77 68.91 1/3/2007 7/1/2009 Outperform 1Y $5.27 +2,665.18% +207.15% +2,458.03 0 Comment
SloopJohnB06 66.83 12/26/2006 Outperform 5Y $5.63 +2,488.37% +210.28% +2,278.08 0 Comment
muae1 < 20 12/18/2006 Outperform NS $5.76 +2,429.95% +206.51% +2,223.43 0 Comment
biogirl < 20 1/8/2007 Outperform 3M $6.45 +2,159.65% +210.58% +1,949.07 0 Comment
opveiby 79.05 1/8/2007 Outperform 1Y $6.46 +2,155.80% +210.52% +1,945.29 0 Comment
Turkmenbashi 44.77 1/8/2007 Outperform 3Y $6.59 +2,111.31% +209.52% +1,901.79 0 Comment

Wall Street

See what the Wall Street professionals think, according to their public statements and filings.

There are no Wall Street tracker picks for SGEN.